Abbott Laboratories (ABT): Director received 432 units
John G Stratton, Director at Abbott Laboratories, reported a grant / award of 432 units.
- 432
- Derivative units · @ $90.74
- Traded
- Jun 30, 2026
- Filed
- Jul 1, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Mar 27, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
- Apr 16, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
- May 7, 2026Insider · Their largest buy since 2019Director purchased ~$174K of ABT shares in the open market
- May 12, 2026FDARecall: Merlin" Patient Care System (PCS) software Merlin" PCS 3650 programmer Model 3330 software
- May 12, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- May 15, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- May 27, 2026Government · Federal Register noticeDrugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Syntest D.S. and Syntest H.S. Tablets; Withdrawal of Hearing Requests; Final Resolution of Drug Efficacy Study Implementation 7661
- May 27, 2026CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
- Jun 12, 2026Congress · 1 personMembers of Congress: 2 purchases
- Jun 16, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
- Jun 17, 2026FDAFDA device clearance: Amplatzer TorqVue Exchange System
What came next
- Jul 2, 2026FDAFDA device clearance: Amplatzer TorqVue LP Delivery System; Amplatzer TorqVue LP Catheter
- Jul 7, 2026Government · Federal Register proposed ruleMedicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; Including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available Slots
- Jul 8, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- Jul 14, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
- Jul 15, 2026FDAFDA device clearance: EnSite X EP System
- Jul 16, 2026Company filing · Form 8-K · ResultsReported its results
- Jul 17, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- Jul 30, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- Aug 6, 2026Government · Federal Register noticeForeign-Trade Zone (FTZ) 39, Notification of Proposed Production Activity; Abbott Laboratories; (Diagnostic Medical Devices); Irving, Texas
- Aug 11, 2026InsiderOfficer sold ~$643K of ABT shares in the open market
- Aug 20, 2026FDARecall: Fisher Scientific Sure-Vue Serum/Urine hCG, Model/ Part: FHC-202/23900529, FHC-202/23900528; Beckman Coulter Inc's ICON 25 hCG, Model/ Part: FHC-202/43025; Hen…
- Aug 20, 2026FDARecall: Fisher Scientific Sure-Vue Urine hCG, Model/ Part: FHC-102/23900526; Henry Schein, Inc. One Step + Urine Cassette Test, Model/ Part: FHC-102/9004074, FHC-102/9…
- Aug 20, 2026FDARecall: McKesson CONSULT hCG Urine Cassette, Model/ Part: FHC-A102/5001; Alere hCG Cassette (20 mIU/mL) in Urine, Model/ Part: FHC-A102/92210; Fisher Scientific Sure-V…
- Aug 20, 2026FDARecall: Fisher Scientific Sure-Vue Urine hCG Strip, Model/ Part: FHC-101/23900527; McKesson CONSULT hCG Urine Test Dipstick CLIA Waived, Model/ Part:FHC-101/5000; Henr…
- Aug 25, 2026Insider · 1 personInsiders: 2 sales (~$46.2M)
- Sep 2, 2026InsiderOfficer sold ~$3K of ABT shares in the open market
- Sep 10, 2026FDARecall: Amplatzer Amulet Left Atrial Appendage Occluder Model Numbers 1. 9-ACP2-007-016 2. 9-ACP2-007-018 3. 9-ACP2-007-020 4. 9-ACP2-007-022 5. 9-ACP2-010-025 6. 9-AC…
- Sep 17, 2026FDAFDA device clearance: EnSite X EP System
- Sep 18, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
- Sep 23, 2026FDAFDA device clearance: Anti-HCV Next
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Abbott Laboratories
For Abbott Laboratories, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 3 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABT page.
Other recent filings by John G Stratton, Director
The full history of John G Stratton, Director is on the profile page.
How this filing works
Explore the data
Common questions
Which Abbott Laboratories (ABT) insider traded, and how much?
John G Stratton, Director at Abbott Laboratories, reported a grant / award of 432 units. At $90.74.
When did it happen, and when was it made public?
Traded: Jun 30, 2026. Filed: Jul 1, 2026. That is 1 day between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Abbott Laboratories recently?
For Abbott Laboratories, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the ABT page.
Does this mean ABT stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Abbott Laboratories
- SEC Form 13F-HRNov 16, 2026
- SEC Form 4Nov 6, 2026
- SEC Form 144Nov 5, 2026
- House Clerk periodic transaction reportOct 30, 2026
- House Clerk periodic transaction reportOct 27, 2026
- House Clerk periodic transaction reportOct 12, 2026
Everything OQRO holds on this company is on its ABT page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
